

1 **Paraoxonase and acylated homoserine lactones in urine from patients with urinary tract infections-**  
2 **- relationship to microbial diversity by 16S rRNA gene sequencing.**

3  
4

5 John Lafleur<sup>1,2\*</sup>, Jacquelyn S. Meisel<sup>3</sup>, Seth Commichaux<sup>3</sup>, Richard L. Amdur<sup>4</sup>, Mihai Pop<sup>3</sup>, Mark W.

6 Silby<sup>2</sup>

7

8 <sup>1</sup>Department Emergency Medicine, George Washington School of Medicine, Washington, DC, United  
9 States of America

10 <sup>2</sup>Department of Biology, University of Massachusetts, Dartmouth, Dartmouth, Massachusetts, United  
11 States of America

12 <sup>3</sup>Department of Computer Science, University of Maryland, College Park, MD, United States of America

13 <sup>4</sup>Department of Surgery, George Washington School of Medicine, Washington, DC, United States of  
14 America

15

16 \*Corresponding author

17 [jlafleur@mfa.gw.edu](mailto:jlafleur@mfa.gw.edu)

18

19

20

21 **Abstract**

22 Paraoxonase (PON) comprises a trio of mammalian enzymes that have been reported to have a number of  
23 roles including the inhibition of bacterial virulence and biofilm formation by microorganisms that quorum  
24 sense with acylated homoserine lactones (AHLs). PON have previously been reported to inhibit *P.*  
25 *aeruginosa* biofilm formation in mammalian airways and skin. An innate immune role for PON in urinary  
26 tract infection has not previously been reported. We performed western blots for PON1 in urine from  
27 patients with urinary tract infection (UTI), and also tested UTI urine for the presence of AHLs using a  
28 cellular reporter system. Urine sample microbiota was assessed through sequencing of the 16S rRNA  
29 marker gene. We report here that PON1 was not found in the urine of control subjects, however, in  
30 patients with UTI, PON1 was associated with the presence of *E. coli* in urine. AHLs, but not PON, were  
31 found in the bulk urine of those with *P. aeruginosa* UTI. Microbial consortia of PON positive UTI urine  
32 was found to be distinct from PON negative UTI urine; differentially over-represented bacteria in PON  
33 positive samples included a number of environmental opportunists. We hypothesize that PON may inhibit  
34 the quorum sensing activity of AHLs in UTI, as has previously described in skin and airways.

35

36

37

38

39

40

41

42

## 43 **Introduction**

44 The paraoxonase family (PONs) of mammalian lactonases are an evolutionarily conserved (1–3) innate  
45 immune mechanism that limit bacterial virulence and biofilm formation by degrading quorum sensing  
46 (QS) acylated homoserine lactones (AHLs) produced by some bacteria (4–13). These AHL-producing  
47 bacteria include *P. aeruginosa*, as well as other environmental opportunists with large genomes and  
48 flexible lifestyles that are frequently found to be occult members of infecting biofilms (14–18). UTIs  
49 caused by such organisms have been reported to be more common in patients with urinary catheters,  
50 diabetes mellitus, and previous hospitalizations (19). In multiple studies PONs have been shown to be  
51 protective against infection by *P. aeruginosa* biofilms in mammalian airways and skin cells (9, 20).  
52 Another body surface that is subject to environmental exposure is the urinary system, and PON1 has  
53 previously been reported in minute concentrations in specialized vesicles in urine from healthy subjects  
54 (21).

55 AHLs are known to be potent activators of quorum sensing that favors biofilm formation and virulence  
56 gene expression in certain gram negative bacteria (22). In parallel, AHLs can directly induce tissue  
57 inflammation and derangement of host immunity (23–27). AHLs have not previously been reported in  
58 urine from human UTI although their presence would have significant implications for the diagnosis and  
59 treatment of UTI.

60 Uncomplicated UTI in an immunocompetent host is characterized by the predominance of a single  
61 bacterial species (28), *E. coli* in 80% of cases. One possibility is that the predominance of *E. coli* in  
62 uncomplicated UTI is due to innate immune activity toward opportunists/difficult to eradicate  
63 environmental strains. In particular, we speculated that environmental opportunists, such as *P.*  
64 *aeruginosa*, are inhibited from quorum sensing with AHLs due to PON activity in the urine. PON has  
65 been shown to limit *P. aeruginosa* virulence in *Drosophila*—a model eukaryotic organism that does not  
66 naturally produce PON (7). PON-deficient mice display increased vulnerability to infection with *P.*

67 *aeruginosa* (29). Whether and how PON is induced in mammalian infection is not at present known in  
68 detail, however protection against *P. aeruginosa*-mediated virulence has been shown to involve induction  
69 of PON2 through peroxisome proliferator-activated receptor-g (30, 31) which is found in mammalian  
70 urothelial cells (32), though the AHL QS molecule (3OC12-HSL) produced by *P. aeruginosa* has been  
71 shown to have inhibitory effect on this receptor (33). Another possibility is that PON are induced through  
72 Toll-like receptors (TLRs) which are cellular sensors for a variety of bacterial factors. Urinary TLR  
73 signaling has been found to be sensitive to uropathogens (34, 35), resulting in activation of NF-kB and the  
74 expression of the pro-inflammatory genes IL-6 and IL-8 with consequent ingress of neutrophils to the  
75 bladder mucosa (36). There is at present, however, no report in the literature of TLR mobilization of  
76 PON. Host disruption of AHL QS through induction of PON has been proposed as protective against  
77 inflammatory bowel disease (37). While urea-mediated inhibition of QS mechanisms in chronic *P.*  
78 *aeruginosa* infection have been shown to limit biofilm formation and other virulence factors without  
79 inhibiting the production of AHLs in a murine CAUTI model (38), in acute UTI with *P. aeruginosa*,  
80 AHL QS has been shown to promote virulence (39). In addition, it has been shown that PON mediates  
81 changes in microbiota in the *Drosophila* gut (40), and in a flow cell model of a polymicrobial consortia  
82 (41). In summary PON are an effector of innate immunity (29, 42) that inhibit bacterial QS-mediated  
83 virulence through degrading the AHL QS signal. In addition, PON have been shown to alter the  
84 composition of host microbiota. To explore possible implications of this in the urinary system, we set out  
85 to measure AHLs and PON in urine from patients with UTI presenting to an emergency department of an  
86 urban hospital. We also assessed the microbiota of study samples through 16S rRNA gene sequencing.  
87 We hypothesized that 1) UTI patients will have PON present, while non-UTI patients will not; 2) among  
88 patients presenting with urinary symptoms (dysuria and frequency) and urinalysis showing elevated urine  
89 leukocytes, the presence of PON will be associated with growth of a urinary pathogen in culture; 3) UTI  
90 urine with PON will be associated with urinary microbiota distinct from that of UTI urine without PON.

91 **Materials and methods**

92 **Human subject enrollment**

93 Study protocol was reviewed/approved by the Miriam Hospital IRB (#496193-16). Written informed  
94 consent was obtained. The study was conducted at the Anderson emergency department of Rhode Island  
95 Hospital. Inclusion criteria for entry into the study: Greater than 18 years of age and able to give informed  
96 consent for study participation; 10 or more white cells in urine analysis with symptoms of urinary tract  
97 infection; urine culture sent to the hospital microbiology department (prior to administration of  
98 antibiotics). Control subjects were emergency department patients with minor complaints unrelated to  
99 urinary system and without significant metabolic derangement such as fever, hyperglycemia, renal disease  
100 (acute or chronic), or significant hypertension. Once enrolled study subjects were asked to provide 50-100  
101 ml of clean-catch urine in a sterile cup. This was immediately frozen at -80 for further study. Culture  
102 results and clinical data were obtained through the electronic medical record at Rhode Island Hospital.

103 **PON and AHL assays**

104 Growth media. Plates and broth were lysogeny broth (LB).

105 Strains. The long chain HSL reporter strain *E. coli* JM109 (pSB1142) (carries *P. aeruginosa lasR* and the  
106 *lasI* promoter fused to *luxCDABE*) (43), and *P. aeruginosa* PAO1 carrying  $P_{lasB}$ -*luxCDABE* (44) were  
107 grown in LB broth with shaking at 37 deg. C.

108 Reagents. 3-oxo-C12-HSL stock solution 20 mg/ml (Cayman Chemicals) was diluted to 4  
109 micrograms/milliliter in water. Dilutions were arrived at empirically by testing against luminescence in  
110 the long chain HSL reporter strain *E. coli* JM109 (pSB1142).

111 **Western blotting.** Urine samples from enrolled research subjects with UTI were stored at -80 deg. C.,  
112 and thawed for use. 25 microliter samples of unprocessed urine were assayed for PON1 using the Bio-  
113 Rad iBlot system as previously described (45).

114 **Antibodies.** Primary antibody: polyclonal human PON1 from rabbit (HPA001610,

115 Atlas Antibodies). Secondary antibody: goat anti-rabbit labeled with peroxidase (Invitrogen)

116 **AHL assay.** Construction of standard curve for 3-oxo-C12-HSL was determined by varying  
117 concentrations of the stock solution diluted in water and incubated with *E coli* JM109 (pSB1142), using a  
118 microtiter plate reading format(46) as previously described (47). 3-oxo-C12-HSL concentrations in  
119 samples were determined by adding 50 microliters of study urine samples to 5 microliters of overnight  
120 sensor strain *E. coli* JM109 (pSB1142) and then measured in a Varioskan Flash plate reader.

121 **Urine Microbiome.** Urine samples, (previously stored at -80 deg C.) in 50 ml quantities, were  
122 centrifuged at 2000 rpm for 20 minutes. Supernatant was poured off, and pellet was resuspended in 1 ml  
123 of sterile water. DNA was extracted using the FastDNA SPIN Kit (MP Biomedicals) (48)

124 **Preparation of 16S rDNA amplicon inserts for Next-Generation library construction and NGS**  
125 **sequence analysis using sequential PCR amplification steps.**

126 Sample preparation and sequencing was performed at the at the UMASS core facility in Shrewsbury, MA.  
127 16S PCR was initially performed to add indexes to individual templates. 10 microliters of DNA template  
128 (10 nanograms) were amplified with primers for 16S V1V2 hypervariable region (figure 1—all primers  
129 were added in 1 microliter volumes from 10 micromolar stock solutions) (49) with Platinum PCR Super  
130 Mix (1306, LifeTech). 45 microliter reaction mixtures were placed in the wells of MicroAmp Fast  
131 Optimal 96-well Reaction Plates (0.1microliter) and run on a 7500 ABI Fast Real-Time PCR System with  
132 the cycling parameters: (95□ 2 min) + 22 x (95□ 45 sec, 50□ 45 sec, 72□ 1 min) + (72□ 7min) + 4□  
133 O/N. Reaction clean-up was performed with Qiagen 96-well PCR cleanup plates; and PCR Product  
134 quantitated and profiled using an Advanced Analytics DNA Fragment Analyzer, Qubit, and NanoVue. A  
135 second 16S PCR was performed to add NGS adapter to barcoded templates with the same protocol (Table  
136 1). Samples were sequenced on an Illumina MiSeq using 300 bp PE chemistry. Reads were processed  
137 and amplicon sequence variants (ASVs) were generated using DADA2 in R. Reads were quality trimmed

138 and filtered using the command fastqPairedFilter using parameters trimLeft=c(10, 20), truncLen=c(240,  
139 200), maxEE=2, rm.phix=TRUE, rm.lowcomplex=5, kmerSize=2. DADA2 was used to learn error rates,  
140 perform sample inference, dereplicate and merge paired end reads, and construct a sequence table.  
141 Taxonomy was assigned using the SILVA 132 ribosomal RNA (rRNA) database.

142 Table 1. Primers 1&2 were used in the first PCR to add barcode; 3&4 in the second PCR reaction to add  
143 NGS adapters

1 Primer F: GCCTCCCTCGCGCCATCAGAGAGTTTGATCMTGGCTCAG
2 Primer R: GCCTTGCCAGCCCGCTCAGCYNACTGCTGCCTCCCGTAG
3 Primer F: 5'-AATGATACGGCGACCACCGANNNAACGTGAGG-3'
4 Primer R: 5'-CAAGCAGAAGACGGCATAACGAGATNNNTACCAGGGTAC-3'

144

#### 145 **Measures**

146 Culture results were recoded into a binary variable (positive/negative). As a sensitivity analysis, we also  
147 coded those patients who were positive but with <50k cfu as negative. Positively skewed continuous  
148 variables and those with outliers were recoded into ordinal variables.

#### 149 **Data analysis.**

150 Associations between diagnosis and categorical variables were analyzed using chi-square or Fishers Exact  
151 Test. Comparison of continuous variables across groups was done using 2-tailed independent groups t-  
152 tests or the Kruskal-Wallis test for skewed variables. In order to test the independent association of PON1  
153 with being culture-positive in UTI patients, we used multivariate logistic regression, adjusting for  
154 variables that might be confounds. These were defined as having an association with PON1 antigen with  
155  $p < .10$ . We also used a multivariable logistic regression model to develop an optimal prediction model for  
156 being culture-positive in UTI patients. This was based on the patient variables that were associated with  
157 being culture-positive with  $p < .10$ , dropping any for which an odds ratio could not be calculated due to  
158 low sample size. SAS version 9.4 (Cary, NC) was used for data analysis, with  $p < .05$  considered  
159 significant.

#### 160 **Microbiome analysis:**

161 A total of 24 samples had sufficient PCR amplification to pass quality control.  
162 These were processed for further analysis with bioinformatics tools as previously described. [ref.] Of  
163 these, 2 were technical controls, and 4 samples were found to have insufficient sequencing depth (< 1,000  
164 reads per sample) and were not included in the analysis. Of the remaining 18 samples, 6 were controls, 5  
165 were UTI/PON-, and 7 UTI/PON+. These 18 samples had a median sequencing depth of 132,986 reads. A  
166 total of 208 OTUs observed more than 3 times in at least 20% of the samples were retained for analysis in  
167 R using the packages phyloseq (50), breakaway (51), DivNet (52), and corncob (53).

168

## 169 **Results**

### 170 **PON and clinical parameters**

171 Mean age of enrolled subjects was  $60 \pm 22$ , 13 (19%) were black and 44 (63%) were white, 48 (69%)  
172 were female, and 11 (16%) had urinary catheters. Culture was positive with one or more uropathogens in  
173 39/61 cases (64%), while western blot for PON1 antigen was positive in 22 cases (36%). There were 61  
174 UTI patients and 9 controls in the sample.

175 Controls and UTI patients differed significantly in age, serum creatinine, highest temperature, and lowest  
176 diastolic blood pressure (Table 2.). Patients with UTI had higher average creatinine, likely due to age-  
177 related decline in kidney function; higher temperature in UTI subjects is likely due to some subjects being  
178 systemically ill.

179

180

181

182

183

184

185



186  
187  
188  
189  
190

**Table 2.** Patient variables by diagnosis (UTI vs control)

Patient variable	Control (n=9)	UTI (n=61)	p
Age	42 ± 16	63 ± 22	.009
Race			.45
Black	3 (33%)	10 (16%)	
White	5 (56%)	39 (64%)	
Other	1 (11%)	12 (20%)	
Gender female	4 (44%)	44 (72%)	.13
Catheterized	0	11 (18%)	.34
WBC	9.3 ± 4.4	11.4 ± 4.4	.25
Hemoglobin	13.7 ± 0.9	12.5 ± 1.9	.07 <sup>A</sup>
Serum creatinine	0.8 ± 0.1	1.2 ± 0.9	.042 <sup>A</sup>
Highest HR	85 ± 14	93 ± 21	.29
Highest temp	97.7 ± 0.6	99.0 ± 1.5	.0001
Lowest systolic bp	123 ± 16	118 ± 20	.40
Lowest diastolic bp	78 ± 11	68 ± 13	.044

191 <sup>A</sup> using Kruskal-Wallis test.

192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202

PON1 was significantly associated with UTI diagnosis. Of the 61 UTI patients, 22 (36%) were PON1 positive, while none of the controls were PON1 positive (Fisher Exact test p=.049). PON1 was not significantly associated with any demographic or laboratory values (Table 3), but was significantly associated with higher heart rate (HR) (Table 3).

203  
204  
205  
206  
207

**Table 3.** Associations between patient variables and PON1 in patients with UTI

Patient variable	PON1 Neg (n=39)	PON1 Pos (n=22)	p
Age	62 ± 22	63 ± 21	.82
Race			.60
Black	5 (13%)	5 (23%)	
White	26 (67%)	13 (59%)	
Other	8 (21%)	4 (18%)	
Gender female	29 (74%)	15 (68%)	.61
Catheterized	5 (13%)	6 (27%)	.18
WBC	11.2 ± 4.4	11.7 ± 4.6	.68
Hemoglobin	12.5 ± 2.0	12.4 ± 1.7	.75
Serum creatinine	1.2 ± 1.0	1.2 ± 0.5	.48
Highest HR	88 ± 16	101 ± 25	.03 <sup>A</sup>
Highest temp	99.0 ± 1.6	98.9 ± 1.3	.66
Lowest systolic bp	120 ± 20	114 ± 20	.27
Lowest diastolic bp	68 ± 12	70 ± 13	.45

208 <sup>A</sup> using Kruskal-Wallis test.

209

210 PON1 was significantly associated with positive culture in UTI patients: PON was positive in 4/22 with  
211 negative culture (18%) versus 18/39 with positive culture (46%; p=.03; Fishers Exact test; Supplemental  
212 Table 1). We did a sensitivity analysis in patients who had culture < 50,000 cfu (culture negative), and  
213 found that the association was still significant (culture negative had 23% PON positive, culture positive  
214 had 48% PON positive, p=.04). Thus, in UTI patients, presence of PON in urine was associated with  
215 urine culture growing out a urinary pathogen, in contrast to urogenital flora, or no growth.

216 In addition to PON1, other patient variables that were associated with being culture-positive, in UTI  
217 patients, included WBC (higher with culture positive), and being catheterized (more frequent for culture  
218 positive). Highest HR was marginally associated with culture-positive (Table Supplemental Table 1.). To  
219 demonstrate the potential clinical utility of PON measurement in UTI we created an optimal prediction  
220 model for being culture-positive, which included PON1, highest HR, and WBC (being catheterized was  
221 dropped because OR could not be calculated for this variable due to small sample size), which had an area  
222 under the ROC curve of 0.72 for predicting culture-positive.

223 Using the equation:  $\text{risk} = -2.43 + 1.007 \cdot \text{PON1} + .014 \cdot \text{highestHR} + .138 \cdot \text{WBC}$ , and then probability =  
224  $\exp(\text{risk}) / (1 + \exp(\text{risk}))$ . Splitting the probabilities into tertiles, we found that the observed incidence of  
225 being culture positive in tertiles 1 through 3, respectively, were 39%, 75%, and 83% ( $p=.01$ ).

226 Half of all positive urine cultures grew out *E. coli* alone (19/38) . PON1 was positive in 10 of these  
227 (53%). When compared to cultures that grew out multiple organisms (including those with ‘urogenital  
228 flora’), PON was significantly associated with cultures that grew out *E. coli* alone,  $P=0.05$  (Supplemental  
229 Table 2.). Seven gram-negative environmental opportunists were cultured from PON negative urines.  
230 Four were *P. aeruginosa*; the others were: *Serratia marscesens*, *Citrobacter freundii*, and *Klebsiella*  
231 *pneumoniae*. These organisms, like *P. aeruginosa*, are multi-drug resistant environmental opportunists.  
232 Additionally these bacteria have all been reported to produce or QS with AHLs.(54–56) Among PON+  
233 urines no such taxa grew out in culture, though, gram negative environmental opportunists were over-  
234 represented as members of the urinary microbiome of PON+ urines (Figure 3).

### 235 **Measurement of AHLs in urine samples**

236 Using an *E. coli* luminescent reporter construct (*E. coli* JM109 (pSB1142)), the presence and abundance  
237 of long chain AHLs was also assayed in urine samples. Long chain AHLs were only detected in three out  
238 of four urine samples that were culture positive for *P. aeruginosa* and PON1 negative. AHL concentration


239 in one sample (patient #9) was about 1.5 micromolar. The other three samples in which *P. aeruginosa*  
240 grew out of culture had considerably lower concentrations (see Supplemental Table 3.).

241

242


### 243 **Urine microbiome**

244 Similar to other human-associated microbiome studies (57), the taxonomic composition of the samples  
245 varied widely across individuals (Figure 1). Shannon diversity, which accounts for the richness and  
246 evenness of taxa within samples, was different between controls and UTI samples, but not between PON+  
247 and PON- UTI samples (Figure 2A , p-value < 0.05). Similarly, Bray Curtis dissimilarity revealed greater  
248 differences between samples based on UTI status, than between PON+ and PON- UTI samples (Figure  
249 2B). A total of 22 taxa were significantly differentially abundant between PON+ and PON- samples when  
250 controlling for differences based on UTI status (Figure 3). Those associated with PON- were typical host  
251 commensals such as *Corynebacterium* and *Peptoniphilus spp.*; all were gram positive cocci. Among the  
252 PON+ group, there was a more diverse group represented including commensals typically associated with  
253 mammalian hosts, and environmental bacteria found in a variety of ecosystems such as *Caulobacter* and  
254 *Aerococcus* which have both been found to cause human infection (58,59).




255  
256  
257

Figure 1. Bars show color-coded proportions of the top 12 taxa in urine microbiome samples, grouped according to UTI and PON status.



258  
259  
260  
261  
262

Figure 2. (A) Differences in Shannon diversity estimates (with confidence intervals) were seen between control and UTI subjects, but not between PON+ and PON- UTI subjects (breakaway beta test,  $p$ -value < 0.05) (B) Beta diversity estimates (with confidence intervals) highlight that control and UTI samples are more dissimilar to each other than PON+ and PON- UTI samples.



263

264

265 Figure 3. A total of 22 OTUs were differentially abundant across PON status when controlling for the effect of UTI status on  
266 abundance. OTUs detected by differentialTest in corncob (FDR adjusted p-values < 0.05). The seven OTUs increased in PON-  
267 samples are all small, gram positive host commensals not otherwise found in the environment. Species over-represented in PON+  
268 samples include environmental opportunists such as *Aerococcus* and *Caulobacter*, as well as human-associated genera such as  
269 *Bacteroides*, *Gardenerella*, *Cutibacterium*, *Prevotella*, and *Staphylococcus*

270

## 271 Discussion

272 PON has previously been shown to inhibit virulence in certain gram-negative pathogens, and to influence  
273 the composition of host microbial consortia. We speculated that PON may have a role in the innate

274 immune response in UTI. Our results indicate a positive association between urine PON and positive  
275 culture in patients with UTI. This finding tends to support the idea that PON may be induced by  
276 uropathogens, and be associated with infections with uropathogens that grow out in culture. Absence of  
277 PON, on the other hand is associated with urine from those without UTI, or, with symptoms of UTI, but  
278 with cultures showing “urogenital flora” (Supplemental Table 2) or, “no growth”. The latter two are urine  
279 culture results which are not considered to represent significant infection. It is notable that in PON+  
280 samples OTUs that were significantly increased, (compared to PON- samples) were more diverse and  
281 contained environmental/opportunistic species (Figure 3), while OTUs differentially found in PON-  
282 samples were a more uniform set of commensals. More generally, the PON+ UTI microbiota was  
283 different than the PON- UTI microbiota—whether this is a result of the presence of PON or PON  
284 expression resulted from pre-existing consortial differences cannot at present be determined. Consortial  
285 differences caused by an AHL quorum quenching enzyme related to PON (SsoPox) was recently reported  
286 by Schwab, et al. (41). They found that in a complex microbial community the addition of an AHL-  
287 degrading enzyme inhibited biofilm formation (even among genera that neither sense nor produce AHLs)  
288 and altered the composition of microbial consortia without changing overall community diversity.  
289 Combined with the present results, Schwab et al.’s findings suggest the possibility that interfering with  
290 AHL signaling can have far-reaching effects on complex microbial communities beyond those limited to  
291 specific effects on species that quorum sense with, or have receptors for, AHLs. In connection with this it  
292 is notable that only PON- urines grew out *P. aeruginosa* or were found to contain AHLs. This may be a  
293 specific effect of PON; there is also evidence that it has more global effects; a practical example is that,  
294 according to our findings, in the complex system consisting of host, uropathogen and urinary microbiota,  
295 information about PON, heart rate, and white blood count can predict the probability of positive urine  
296 cultures.

297 In our study PON positive subjects had significantly more UTIs caused by *E. coli* alone, rather than multi-  
298 species infections, or infections with opportunists such as *P. aeruginosa*. It has previously been reported

299 that the large majority of uncomplicated UTIs in normal hosts are caused by single species (28). Infection  
300 associated with impaired immunity is characterized by difficult to eradicate biofilms, polymicrobial  
301 infections, and infection with opportunistic organisms that don't readily infect immune-competent hosts.  
302 PON positive subjects featured microbiota with a larger proportion of opportunists, but greater likelihood  
303 of single-pathogen urine cultures, suggesting that PON may contribute to immunocompetence. PON-  
304 urines grew out more environmental opportunists in culture, compared to PON+ urines, (which grew out  
305 none as the primary uropathogen). As noted, the microbiota of PON positive urine in patients with UTI  
306 contained a larger proportion of environmental/opportunistic bacteria; whether or not the presence of  
307 opportunistic bacteria induces PON (which may then limit their ability to become primary uropathogen)  
308 can't be determined at present. Nonetheless, the role of PON in innate immunity of the airway and skin  
309 (9, 20, 60), suggests that urinary PON may also have a protective role. This may occur through degrading  
310 the virulence-associated AHLs of some uropathogens, and independently as a mediator of inflammation.  
311 Another possible protective effective of PON relates to its putative effects on microbial consortia, and the  
312 possibility that host benefits are realized as a result.

313 We also report here for the first time AHLs in urine from subjects with UTI. C12 AHL levels in urine  
314 from subjects with *P. aeruginosa* UTI have not previously been reported, though detection in urine of  
315 non-AHL *P. aeruginosa* mediators of QS associated with pulmonary infection has recently been reported  
316 (61). In the current study, 3 out of 4 urine samples from which *Pseudomonas* grew out in culture were  
317 found to have detectable levels of C12 AHLs. Two of three were below 1 micromolar (Table 5.)  
318 Biologically relevant concentrations of AHLs for QS are considered to be 1-5 micromolar (26), and levels  
319 of C12 AHL in planktonic cultures necessary to initiate QS-related *lasB* expression have previously been  
320 reported to be about 1 micromolar (62). This is a concentration of C12 AHLs that is not uncommonly  
321 seen in planktonic cultures of *P. aeruginosa*. By contrast, C12 AHL levels associated with *P. aeruginosa*  
322 biofilms in flow cells have been found to be hundreds of times higher (63). One possible interpretation of  
323 concentrations of C12 considerably below this in three of four samples suggests that QS and virulence



324 expression in *P. aeruginosa* UTI is not a planktonic phenomenon in the urine. QS may be occurring on  
325 mucosal surfaces of the bladder/urinary system with bacterial surface colonization where local  
326 concentrations of metabolites such as AHLs are likely to be much higher (64), and interactions with  
327 mediators of host immunity more intense (65). Urine has recently been reported to independently promote  
328 *P. aeruginosa* biofilm formation (66), suggesting that even in the absence of the normal QS-mediated  
329 mechanisms for biofilm formation, a biofilm may still be formed in *P. aeruginosa* UTI.

### 330 **Conclusion**

331 We report for the first time AHLs in the urine of subjects with *P. aeruginosa* UTIs; the significance of  
332 this, and the role that AHLs play in QS among planktonic *P. aeruginosa* remains to be investigated; our  
333 finding suggests that QS mechanisms may affect UTI-related microbial consortia, and possibly microbial  
334 pathogenesis in UTI. We found that UTI subjects with PON positive urines were much more likely to  
335 have uncomplicated *E. coli* UTI. The presence of PON was associated with distinct microbial consortia in  
336 which differentially over-represented genera were more diverse, and included opportunistic  
337 environmental species. Future work may address the question of whether PON is induced in  
338 circumstances in which uropathogens might otherwise establish difficult to eradicate polymicrobial  
339 infections more often seen in immunocompromised hosts.

340

341

342

343

344

345

346

347 **References**

- 348 1. Bar-Rogovsky H, Hugenmatter A, Tawfik DS. 2013. The evolutionary origins of detoxifying  
349 enzymes: the mammalian serum paraoxonases (PONs) relate to bacterial homoserine lactonases. *J*  
350 *Biol Chem* 288:23914–27.
- 351 2. Elias M, Tawfik DS. 2012. Divergence and convergence in enzyme evolution: parallel evolution  
352 of paraoxonases from quorum-quenching lactonases. *J Biol Chem* 287:11–20.
- 353 3. Khersonsky O, Tawfik DS. 2005. Structure-reactivity studies of serum paraoxonase PON1 suggest  
354 that its native activity is lactonase. *Biochemistry* 44:6371–6382.
- 355 4. Chun CK, Ozer EA, Welsh MJ, Zabner J, Greenberg EP. 2004. Inactivation of a *Pseudomonas*  
356 *aeruginosa* quorum-sensing signal by human airway epithelia. *Proc Natl Acad Sci U S A*  
357 101:3587–3590.
- 358 5. Ozer E a, Pezzulo A, Shih DM, Chun C, Furlong C, Lusic AJ, Greenberg EP, Zabner J. 2005.  
359 Human and murine paraoxonase 1 are host modulators of *Pseudomonas aeruginosa* quorum-  
360 sensing. *FEMS Microbiol Lett* 253:29–37.
- 361 6. Manolescu B. 2013. Paraoxonases as Protective Agents Against N-Acyl Homoserine Lactone-  
362 Producing Pathogenic Microorganisms. *Maedica (Buchar)* 8:49–52.
- 363 7. Stoltz DA, Ozer EA, Taft PJ, Barry M, Liu L, Kiss PJ, Moninger TO, Parsek MR, Zabner J. 2008.  
364 *Drosophila* are protected from *Pseudomonas aeruginosa* lethality by transgenic expression of  
365 paraoxonase-1. *J Clin Invest* 118:3123–3131.
- 366 8. Stoltz DA, Ozer EA, Ng CJ, Janet MY, Reddy ST, Lusic AJ, Bourquard N, Parsek MR, Zabner J,  
367 Shih DM. 2007. Paraoxonase-2 deficiency enhances *Pseudomonas aeruginosa* quorum sensing in  
368 murine tracheal epithelia. *Am J Physiol Cell Mol Physiol* 292:L852–L860.
- 369 9. Simanski M, Babucke S, Eberl L, Harder J. 2012. Paraoxonase 2 acts as a quorum sensing-  
370 quenching factor in human keratinocytes. *J Invest Dermatol* 132:2296–9.
- 371 10. Devarajan A, Bourquard N, Grijalva VR, Gao F, Ganapathy E, Verma J, Reddy ST. 2013. Role of  
372 PON2 in innate immune response in an acute infection model. *Mol Genet Metab* 110:362–70.
- 373 11. Schweikert E-M, Amort J, Wilgenbus P, Förstermann U, Teiber JF, Horke S. 2012. Paraoxonases-  
374 2 and -3 Are Important Defense Enzymes against *Pseudomonas aeruginosa* Virulence Factors due  
375 to Their Anti-Oxidative and Anti-Inflammatory Properties. *J Lipids* 2012:352857.
- 376 12. Amara N, Krom BP, Kaufmann GF, Meijler MM. 2011. Macromolecular inhibition of quorum  
377 sensing: enzymes, antibodies, and beyond. *Chem Rev* 111:195–208.
- 378 13. Gowda LK, Marie MAM. 2014. Role of quorum-sensing molecules in infections caused by Gram-  
379 negative bacteria and host cell response. *Rev Med Microbiol* 25:66–70.
- 380 14. Dubern J-F, Cigana C, De Simone M, Lazenby J, Juhas M, Schwager S, Bianconi I, Döring G,  
381 Eberl L, Williams P, Bragonzi A, Cámara M. 2015. Integrated whole-genome screening for  
382 *Pseudomonas aeruginosa* virulence genes using multiple disease models reveals that pathogenicity

- 383 is host specific. *Environ Microbiol* 17:4379–4393.
- 384 15. Tümmler B, Wiehlmann L, Klockgether J, Cramer N. 2014. Advances in understanding  
385 *Pseudomonas*. *F1000Prime Rep* 6:9.
- 386 16. Davenport PW, Griffin JL, Welch M. 2015. Quorum Sensing Is Accompanied by Global  
387 Metabolic Changes in the Opportunistic Human Pathogen *Pseudomonas aeruginosa*. *J Bacteriol*  
388 197:2072–2082.
- 389 17. Vincenti S, Quaranta G, De Meo C, Bruno S, Ficarra MG, Carovillano S, Ricciardi W, Laurenti P.  
390 2014. Non-fermentative gram-negative bacteria in hospital tap water and water used for  
391 haemodialysis and bronchoscope flushing: Prevalence and distribution of antibiotic resistant  
392 strains. *Sci Total Environ* 499:47–54.
- 393 18. Brooke JS. 2012. *Stenotrophomonas maltophilia*: An emerging global opportunistic pathogen. *Clin*  
394 *Microbiol Rev* 25:2–41.
- 395 19. Solanki R, Dawar R. 2015. Nonfermenting Gram-Negative Bacilli and Urinary Tract Infection -  
396 Sorting the Mystery of Infections Caused. *J Med Microbiol Diagnosis* 04:2–5.
- 397 20. Stoltz DA, Ozer EA, Zabner J. 2008. Paraoxonases, Quorum Sensing, And *Pseudomonas*  
398 *Aeruginosa*, p. 307–319. *In The Paraoxonases: Their Role in Disease Development and*  
399 *Xenobiotic Metabolism*. Springer Netherlands, Dordrecht.
- 400 21. Lescuyer P, Pernin A, Hainard A, Bigeire C, Burgess JA, Zimmermann-Ivol C, Sanchez JC,  
401 Schifferli JA, Hochstrasser DF, Moll S. 2008. Proteomic analysis of a podocyte vesicle-enriched  
402 fraction from human normal and pathological urine samples. *ProteomicsClinical Appl* 2:1008–  
403 1018.
- 404 22. Passos da Silva D, Schofield MC, Parsek MR, Tseng BS. 2017. An update on the  
405 sociomicrobiology of quorum sensing in gram-negative biofilm development. *Pathogens* 6:1–9.
- 406 23. Boontham P, Robins A, Chandran P, Pritchard D, Camara M, Williams P, Chuthapisith S,  
407 McKechnie A, Rowlands BJ, Eremin O. 2008. Significant immunomodulatory effects of  
408 *Pseudomonas aeruginosa* quorum-sensing signal molecules: possible link in human sepsis. *Clin*  
409 *Sci (Lond)* 115:343–351.
- 410 24. Hartmann A, Schikora A. 2012. Quorum sensing of bacteria and trans-kingdom interactions of N-  
411 acyl homoserine lactones with eukaryotes. *J Chem Ecol* 38:704–13.
- 412 25. Li Y, Zhou H, Zhang Y, Chen C, Huang B, Qu P, Zeng J, E S, Zhang X, Liu J. 2015. N-3-  
413 (oxododecanoyl)-L-homoserine lactone promotes the induction of regulatory T-cells by preventing  
414 human dendritic cell maturation. *Exp Biol Med* 240:896–903.
- 415 26. Kravchenko V V., Kaufmann GF, Mathison JC, Scott D a., Katz AZ, Wood MR, Brogan AP,  
416 Lehmann M, Mee JM, Iwata K, Pan Q, Fearn C, Knaus UG, Meijler MM, Janda KD, Ulevitch  
417 RJ. 2006. N-(3-oxo-acyl)homoserine lactones signal cell activation through a mechanism distinct  
418 from the canonical pathogen-associated molecular pattern recognition receptor pathways. *J Biol*  
419 *Chem* 281:28822–28830.
- 420 27. Kravchenko V, Garner AL, Mathison J, Seit-Nebi A, Yu J, Gileva IP, Ulevitch R, Janda KD.  
421 2013. Facilitating Cytokine-Mediated Cancer Cell Death by Proteobacterial N -Acylhomoserine  
422 Lactones. *ACS Chem Biol* 8:1117–1120.

- 423 28. Willner D, Low S, Steen J a., George N, Nimmo GR, Schembri M a., Hugenholtz P. 2014. Single  
424 clinical isolates from acute uncomplicated urinary tract infections are representative of dominant  
425 In Situ populations. *MBio* 5:1–10.
- 426 29. Devarajan A, Bourquard N, Grijalva VR, Gao F, Ganapathy E, Verma J, Reddy ST. 2013. Role of  
427 PON2 in innate immune response in an acute infection model. *Mol Genet Metab* 110:362–370.
- 428 30. Maurice NM, Bedi B, Sadikot RT. 2018. *Pseudomonas aeruginosa* biofilms: Host response and  
429 clinical implications in lung infections. *Am J Respir Cell Mol Biol* 58:428–439.
- 430 31. Bedi B, Maurice NM, Ciavatta VT, Lynn KS, Yuan Z, Molina SA, Joo M, Tyor WR, Goldberg  
431 JB, Koval M, Hart CM, Sadikot RT. 2017. Peroxisome proliferator-activated receptor- $\gamma$  agonists  
432 attenuate biofilm formation by *Pseudomonas aeruginosa*. *FASEB J* 31:3608–3621.
- 433 32. Guan Y, Zhang Y, Davis L, Breyer MD. 1997. Expression of peroxisome proliferator-activated  
434 receptors in urinary tract of rabbits and humans. *Am J Physiol - Ren Physiol* 273.
- 435 33. Jahoor A, Patel R, Bryan A, Do C, Krier J, Watters C, Wahli W, Li G, Williams SC, Rumbaugh  
436 KP. 2008. Peroxisome proliferator-activated receptors mediate host cell proinflammatory  
437 responses to *Pseudomonas aeruginosa* autoinducer. *J Bacteriol* 190:4408–4415.
- 438 34. Ragnarsdóttir B, Jönsson K, Urbano A, Grönberg-Hernandez J, Lutay N, Tammi M, Gustafsson  
439 M, Lundstedt A-C, Leijonhufvud I, Karpman D, Wullt B, Truedsson L, Jodal U, Andersson B,  
440 Svanborg C. 2010. Toll-like receptor 4 promoter polymorphisms: common TLR4 variants may  
441 protect against severe urinary tract infection. *PLoS One* 5:e10734.
- 442 35. Ingersoll M a, Albert ML. 2013. From infection to immunotherapy: host immune responses to  
443 bacteria at the bladder mucosa. *Mucosal Immunol* 6:1041–53.
- 444 36. Nielubowicz GR, Mobley HLT. 2010. Host-pathogen interactions in urinary tract infection. *Nat*  
445 *Rev Urol* 7:430–441.
- 446 37. Coquant G, Grill JP, Seksik P. 2020. Impact of N-Acyl-Homoserine Lactones, Quorum Sensing  
447 Molecules, on Gut Immunity. *Front Immunol* 11:1–8.
- 448 38. Cole SJ, Hall CL, Schniederberend M, Farrow JM, Goodson JR, Pesci EC, Kazmierczak BI, Lee  
449 VT. 2018. Host suppression of quorum sensing during catheter-associated urinary tract infections.  
450 *Nat Commun* 9:1–8.
- 451 39. Gupta RK, Chhibber S, Harjai K. 2013. Quorum sensing signal molecules cause renal tissue  
452 inflammation through local cytokine responses in experimental UTI caused by *Pseudomonas*  
453 *aeruginosa*. *Immunobiology* 218:181–5.
- 454 40. Pezzulo AA, Hornick EE, Rector M V., Estin M, Reisetter AC, Taft PJ, Butcher SC, Carter AB,  
455 Manak JR, Stoltz DA, Zabner J. 2012. Expression of Human Paraoxonase 1 Decreases Superoxide  
456 Levels and Alters Bacterial Colonization in the Gut of *Drosophila melanogaster*. *PLoS One* 7:1–8.
- 457 41. Schwab M, Bergonzi C, Sakkos J, Staley C, Zhang Q, Sadowsky MJ, Aksan A, Elias M. 2019.  
458 Signal disruption leads to changes in bacterial community population. *Front Microbiol* 10:1–13.
- 459 42. Carusone TM, Cardiero G, Cerreta M, Mandrich L, Moran O, Porzio E, Catara G, Lacerra G,  
460 Manco G. 2020. WTAP and BIRC3 are involved in the posttranscriptional mechanisms that  
461 impact on the expression and activity of the human lactonase PON2. *Cell Death Dis* 11.

- 462 43. Winson MK, Swift S, Fish L, Throup JP, Jørgensen F, Chhabra SR, Bycroft BW, Williams P,  
463 Stewart GSAB. 1998. Construction and analysis of luxCDABE-based plasmid sensors for  
464 investigating N-acyl homoserine lactone-mediated quorum sensing. *FEMS Microbiol Lett*  
465 163:185–192.
- 466 44. Hraiech S, Hiblot J, Lafleur J, Lepidi H, Papazian L, Rolain J-M, Raoult D, Elias M, Silby MW,  
467 Bzdrenga J, Bregeon F, Chabriere E. 2014. Inhaled Lactonase Reduces *Pseudomonas aeruginosa*  
468 Quorum Sensing and Mortality in Rat Pneumonia. *PLoS One* 9:e107125.
- 469 45. Lin-Moshier Y, Marchant JS. 2013. A rapid Western blotting protocol for the *Xenopus* oocyte.  
470 *Cold Spring Harb Protoc* 2013:10.1101/pdb.prot072793 [pdb.prot072793](https://doi.org/10.1101/pdb.prot072793).
- 471 46. Dietrich JA, McKee AE, Keasling JD. 2010. High-throughput metabolic engineering: advances in  
472 small-molecule screening and selection. *Annu Rev Biochem* 79:563–90.
- 473 47. Pérez-Montaña F, Jiménez-Guerrero I, Contreras Sánchez-Matamoros R, López-Baena FJ, Ollero  
474 FJ, Rodríguez-Carvajal MA, Bellogín RA, Espuny MR. 2013. Rice and bean AHL-mimic quorum-  
475 sensing signals specifically interfere with the capacity to form biofilms by plant-associated  
476 bacteria. *Res Microbiol* 164:749–760.
- 477 48. Dhaliwal A. 2013. DNA Extraction and Purification. *Mater Methods* 3:1–23.
- 478 49. Siddiqui H, Nederbragt AJ, Lagesen K, Jeansson SL, Jakobsen KS. 2011. Assessing diversity of  
479 the female urine microbiota by high throughput sequencing of 16S rDNA amplicons. *BMC*  
480 *Microbiol* 11:244.
- 481 50. McMurdie PJ, Holmes S. 2013. phyloseq: An R Package for Reproducible Interactive Analysis  
482 and Graphics of Microbiome Census Data. *PLoS One* 8:e61217.
- 483 51. Willis A, Bunge J, Whitman T. 2017. Improved detection of changes in species richness in high  
484 diversity microbial communities. *J R Stat Soc Ser C (Applied Stat)* 66:963–977.
- 485 52. Willis AD, Martin BD. 2020. Estimating diversity in networked ecological communities.  
486 *Biostatistics* <https://doi.org/10.1093/biostatistics/kxaa015>.
- 487 53. Martin BD, Witten D, Willis AD. 2020. Modeling microbial abundances and dysbiosis with beta-  
488 binomial regression. *Ann Appl Stat* 14:94–115.
- 489 54. Annapoorani A, Jabbar AKKA, Musthafa SKS, Pandian SK, Ravi AV. 2012. Inhibition of  
490 Quorum Sensing Mediated Virulence Factors Production in Urinary Pathogen *Serratia marcescens*  
491 PS1 by Marine Sponges. *Indian J Microbiol* 52:160–166.
- 492 55. Hentzer M, Givskov M. 2003. Pharmacological inhibition of quorum sensing for the treatment of  
493 chronic bacterial infections. *J Clin Invest* 112:1300–1307.
- 494 56. Yin W, Purmal K, Chin S, Chan X-Y, Koh C, Sam C, Chan K. 2012. N-Acyl Homoserine Lactone  
495 Production by *Klebsiella pneumoniae* Isolated from Human Tongue Surface. *Sensors* 12:3472–  
496 3483.
- 497 57. Gilbert JA, Blaser MJ, Caporaso JG, Jansson JK, Lynch S V., Knight R. 2018. Current  
498 understanding of the human microbiome. *Nat Med* 24:392–400.
- 499 58. Justesen US, Holt HM, Thiesson HC, Blom J, Nielsen XC, Dargis R, Kemp M, Christensen JJ.  
500 2007. Report of the first human case of *Caulobacter* sp. infection. *J Clin Microbiol* 45:1366–1369.

- 501 59. Rasmussen M. 2016. *Aerococcus*: An increasingly acknowledged human pathogen. *Clin Microbiol*  
502 *Infect* 22:22–27.
- 503 60. Zhang L, Gowardman J, Morrison M, Krause L, Playford EG, Rickard CM. 2014. Molecular  
504 investigation of bacterial communities on intravascular catheters: No longer just *Staphylococcus*.  
505 *Eur J Clin Microbiol Infect Dis* 33:1189–1198.
- 506 61. Barr HL, Halliday N, Camara M, Barrett D a., Williams P, Forrester DL, Simms R, Smyth a. R,  
507 Honeybourne D, Whitehouse JL, Nash EF, Dewar J, Clayton a., Knox a. J, Fogarty a. W. 2015.  
508 *Pseudomonas aeruginosa* quorum sensing molecules correlate with clinical status in cystic fibrosis.  
509 *Eur Respir J* 1–9.
- 510 62. Pearson JP, Passador L, Iglewski BH, Greenberg EP. 1995. A second N-acylhomoserine lactone  
511 signal produced by *Pseudomonas aeruginosa*. *Proc Natl Acad Sci U S A* 92:1490–1494.
- 512 63. Charlton TS, de Nys R, Netting a, Kumar N, Hentzer M, Givskov M, Kjelleberg S. 2000. A novel  
513 and sensitive method for the quantification of N-3-oxoacyl homoserine lactones using gas  
514 chromatography-mass spectrometry: application to a model bacterial biofilm. *Environ Microbiol*  
515 2:530–541.
- 516 64. Stickler DJ, Morris NS, McLean RJ, Fuqua C. 1998. Biofilms on indwelling urethral catheters  
517 produce quorum-sensing signal molecules in situ and in vitro. *Appl Environ Microbiol* 64:3486–  
518 3490.
- 519 65. Greene SE, Hibbing ME, Janetka J, Chen SL, Hultgren J. 2015. Human Urine Decreases Function  
520 and Expression of Type 1 Pili in Uropathogenic *Escherichia coli*. *MBio* 6:1–9.
- 521 66. Cole SJ, Records AR, Orr MW, Linden SB, Lee VT. 2014. Catheter-associated urinary tract  
522 infection by *Pseudomonas aeruginosa* is mediated by exopolysaccharide-independent biofilms.  
523 *Infect Immun* 82:2048–2058.
- 524